Document is current

Article History

Received: 19 January 2026

Accepted: 20 February 2026

First Online: 24 February 2026

Declarations

:

: The study was approved by the Data Protection Office at Oslo University Hospital and the South-Eastern Regional Ethical Committee (reference number: 21/02197).

: PB has received grants from The Norwegian Cancer Society South–Eastern Norway Regional Health Authority. He has received payment as a testimony expert from The Norwegian Expert Panel. He is member of the EANO guideline committee, and leader of The Norwegian Neuro-Oncology Group. EOVM has received grants from the Norwegian Cancer Society South-Eastern Norway Regional Health Authority, The Norwegian Brain Cancer Society, and The Norwegian Child Cancer Society. He has a leader role in the Norwegian Brain Tumor Consortium and the Scandinavian Society of Neurosurgery. EOVM has received payments for lectures from Brainlab AG, Germany and received travel reimbursements for lectures from Oxford Nanopore Technologies. LN has received grants from the Leukemia and Lymphoma Society and NIH/NCI. She has revied Royalties from Wolters Kulwer, and consulting fees from Ono, Brave Bio, Genmab and Curis. LN has received payment for lectures from Ono and Astra Zenaca. She has participated in the data safety monitoring board in Kite/Gilead, Ono, Miltenyi, and Curis. She has received clinical trail support from Merck, Astra Zeneca, Kazia, Ono and Curis.